Seegene Establishes French Branch to Enhance European Market Presence

Seegene Opens New Office in France to Boost European Reach

Seegene, Inc., a global leader in molecular diagnostics (MDx), has taken a significant step by establishing a new subsidiary in France. This marks the company's eighth commercial entity globally and its third in Europe, following Italy and Germany. The French market is recognized as the second-largest in Europe for molecular diagnostics, representing approximately 15% of the overall European landscape.

The demand for various diagnostic tests in France, particularly those targeting sexually transmitted infections (STIs), gastrointestinal infections, and respiratory infections, is driving this expansion. By launching this local entity, Seegene aims to bolster its connections with customers and partners, ensuring enhanced technical support, market development, and collaboration with health sector stakeholders.

The Potential of the French Market

According to market research firm Grand View Research, the French molecular diagnostics market is valued at about 600 million euros, placing it right after Germany, which holds a 19% market share. The rising prevalence of infectious diseases necessitates advanced diagnostic solutions, and Seegene is well-positioned to address these needs through its innovative products.

Seegene is optimistic that the establishment of this subsidiary will facilitate the growth of its product offerings, particularly in areas such as cervical cancer detection and other multiplex testing categories. As described by Daniel Shin, Executive Vice President and Chief Sales & Marketing Officer, the ability to swiftly provide innovative products and meet laboratory efficiency demands is crucial for maintaining a competitive edge in the private and public segments of the French market.

Strategic Goals and Future Plans

The new entity not only strengthens Seegene’s sales capabilities but also serves as a strategic anchor for deploying its evolving solutions in Europe. Key developments such as CURECA™, a fully automated PCR system, and STAgora™, a real-time epidemiological data analysis platform, will benefit from enhanced access to the French healthcare landscape.

With the addition of France, Seegene’s commercial operations now encompass eight subsidiaries worldwide, supported by a network of 90 distributors across 94 countries. This expansion is part of Seegene’s broader strategy, which has seen international sales accounting for 93% of its total revenue in the first half of 2025, with Europe contributing 63% of this figure.

Conclusion

The establishment of the French subsidiary marks a significant milestone for Seegene as it seeks to expand its footprint in the European market. With its commitment to providing innovative diagnostic solutions and strengthening local service, Seegene is poised for continued growth in this vital region. The company’s robust portfolio, highlighted during the COVID-19 pandemic through the provision of over 340 million COVID-19 tests to more than 100 countries, demonstrates its ability to address complex healthcare challenges effectively.

For more information about Seegene and its innovative products, visit Seegene's official website or follow them on LinkedIn.